Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117253 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2TDP1MAPTKDM4ETHRB | |
| SCHEMBL7119570 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2TDP1MAPTKDM4ETHRB | |
| SCHEMBL7119567 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2TDP1MAPTKDM4ETHRB | |
| SCHEMBL11234237 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2TDP1MAPTKDM4ETHRB | |
| SCHEMBL11234232 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2TDP1MAPTKDM4ETHRB | |
| SCHEMBL2294810 | 0.80 | CYP1A2 (0.42) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL4879818 | 0.80 | CYP1A2 (0.42) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL5656969 | 0.80 | KDM4E (0.38) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL6470507 | 0.80 | KDM4E (0.38) | SMN1; SMN2MAPTKDM4ETHRBALOX15 | |
| SCHEMBL9966095 | 0.80 | KDM4E (0.38) | SMN1; SMN2MAPTKDM4ETHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6808716-B2 | N-acetylamino acids, related N-acetyl compounds and their topical use | YU RUEY J (US) | 2004-10-26 | — | — | US | claimed |
| WO-2004089329-A2 | TOPICAL COMPOSITIONS COMPRISING N-ACETYLAMINO ACIDS OR RELATED N-ACETYL COMPOUNDS | YU RUEY J (US) | 2004-10-21 | — | — | WO | claimed |
| US-20030198656-A1 | N-acetylamino acids, related N-acetyl compounds and their topical use | YU RUEY J (US) | 2003-10-23 | — | — | US | claimed |
| US-5728373-A | EXHIBITING DEEP SKIN PENETRATION | BEIERSDORF AG (DE) | 1998-03-17 | — | — | US | claimed |
| EP-0656774-B1 | COSMETIC AND DERMATOLOGICAL SUNSCREEN COMPOSITIONS CONTAINING THIOLS AND/OR THIOL DERIVATES | BEIERSDORF AG (DE) | 1997-01-22 | — | — | EP | claimed |
| US-6808716-B2 | N-acetylamino acids, related N-acetyl compounds and their topical use | YU RUEY J (US) | 2004-10-26 | — | — | US | disclosed |
| WO-2004089329-A2 | TOPICAL COMPOSITIONS COMPRISING N-ACETYLAMINO ACIDS OR RELATED N-ACETYL COMPOUNDS | YU RUEY J (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20030229141-A1 | N-acetyl cysteine and its topical use | YU RUEY J (US) | 2003-12-11 | — | — | US | disclosed |
| US-6649609-B2 | For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children | NEUROSEARCH A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030198656-A1 | N-acetylamino acids, related N-acetyl compounds and their topical use | YU RUEY J (US) | 2003-10-23 | — | — | US | disclosed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | SMN1; SMN2 729/4885TDP1 3813/4885MAPT 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.